Skip to main content
. 2015 Jun 2;84(22):2247–2257. doi: 10.1212/WNL.0000000000001642

Figure 2. Summary of the longitudinal analyses of NfL levels in the London and Oxford cohorts.

Figure 2

Observed trajectories of log NfL levels in the 15-month follow-up period for individual patients with ALS (dashed lines) and the predicted average trajectories (solid lines) are shown for ALS-fast (red), ALS-intermediate (green), and ALS-slow (blue) patients in the London cohort (plasma, panel A) and Oxford cohort (serum, panel B; CSF, panel C). ALS-fast: progression rate at last visit (PRL) >1.0; ALS-intermediate: PRL 0.5–1.0; ALS-slow: PRL <0.5. ALS = amyotrophic lateral sclerosis; NfL = neurofilament light chain.

HHS Vulnerability Disclosure